Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

A user is experiencing uneven hair thinning and has tried topical minoxidil without success and finasteride with adverse effects. They are considering microneedling and PRP treatments while avoiding finasteride, and another user suggests trying dutasteride as an alternative.

A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

A user is asking about the effectiveness and dosage of RU58841 for hair loss, comparing it to Minoxidil and discussing its long-term use alongside Finasteride. They plan to use RU58841 and Finasteride for several years before potentially switching to GT20029.

The user experienced hairline improvement using microneedling once a month with a 12-pin set at 1.5-2.0mm and taking Tru Niagen, alongside a heavily modified diet. They attribute the slow hairline improvement to environmental factors, particularly diet, rather than solely genetic factors.

User gained hair with topical minoxidil and finasteride, then experienced shedding after starting pyrilutamide. After 12 weeks, new hairs grew and existing hairs thickened, hoping for more improvement in a year.

The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.

The user has been using Actifolic Pyrilutamide 0.5% once daily for almost three weeks without noticing any side effects or progress. Other users suggest that significant results typically take 3-6 months to appear.

The user started treating their slightly thinning, receded hairline with a serum containing Redensyl and other ingredients, and dermarolling weekly. They recently began taking finasteride and plan to stop Redensyl in the future to test if hair loss resumes.

The user shared a 3-month progress update on hair loss treatment using oral finasteride, oral minoxidil, dutasteride, ketoconazole, biotin, collagen shampoo, dermarolling, and scalp massage, noting some side effects like decreased libido and low mood. The user received feedback and questions about their regimen, including why both finasteride and dutasteride are used.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

The user has seen positive results after 16 months of using topical Finasteride/Minoxidil, microneedling weekly, and Tretinoin for hair loss. There are no reported side effects, and the user advises that the effectiveness of microneedling depends on the pressure applied.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The user has been using a combination spray with 0.1% finasteride, 5% minoxidil, and tretinoin for over a year but feels their hairline has worsened. They are considering increasing the concentration of finasteride and adding 5% minoxidil once a day, while another user suggests trying oral finasteride for potentially better results.

User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.

The user experienced hair thinning on TRT and considered various treatments suggested by an online clinic, including GHK-Cu Scalp Serum and Minoxidil blends. The consensus is that only finasteride or dutasteride effectively stop hair loss, while Minoxidil can thicken hair.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

RU58841 alone had mixed results; some users combined it with minoxidil. One user experienced side effects with finasteride and maintained with RU58841 and minoxidil, but noted possible chest pain.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.

The user started oral finasteride, switched to oral dutasteride, oral minoxidil, and microneedling, and is seeing potential hair thickening. Others agree there is regrowth and suggest continuing treatment.

Using a combination of finasteride, minoxidil, dermarolling, and RU58841 to treat hair loss. Participants discussed the time commitment required for treatment and the effectiveness of different dosages.

A user shared progress pictures claiming significant hair regrowth using topical minoxidil, finasteride, and weekly microneedling, but faced skepticism and accusations of using someone else's photos. The user clarified that both they and a friend used these treatments, with the friend showing results in the pictures.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

After 8 months of using topical finasteride, hair miniaturization continues, raising concerns about its effectiveness. Microneedling is suggested as a possible complementary treatment.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.